Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 14/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192766 | 0.93 | SMYD3 (0.68) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL29130708 | 0.88 | SMYD3 (0.63) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL4935353 | 0.86 | SMYD3 (0.74) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL3193145 | 0.85 | SMYD3 (0.71) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL26301 | 0.84 | SMYD3 (0.71) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL3182105 | 0.84 | SMYD3 (0.71) | SMYD3ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL19701263 | 0.84 | SMYD3 (1.00) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL3182622 | 0.84 | SMYD3 (0.70) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL3195896 | 0.81 | SMYD3 (0.67) | SMYD3HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL19710291 | 0.81 | SMYD3 (1.00) | SMYD3HDAC3HDAC4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | disclosed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | GSK3B, GSK3A, GSKIP | SMYD3 1122/4885ALDH1A1 2460/4885HDAC3 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.